Literature DB >> 18568292

FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report.

Cécile Colavolpe1, Eric Guedj, Philippe Metellus, Maryline Barrie, Dominique Figarella-Branger, Olivier Mundler, Olivier Chinot.   

Abstract

True multicentric glioblastoma multiforme (GBM) is rare and consists of separate distinct tumors in different cerebral lobes or hemispheres without any apparent route of dissemination. Few data are available describing its imaging using positron emission tomography (PET) with [18F]-fluoro-2-deoxy-D: -glucose (FDG). In this paper, we report on the case of a man with bifocal tumor in the right frontal and temporal lobes who underwent FDG-PET imaging. Visual and semiquantitative analysis showed two different metabolic patterns with much more intense uptake in the smaller temporal lesion. Subtotal surgical removal of the main frontal lesion allowed satisfactory control in the operative site, whereas the temporal lesion was rapidly progressive with occurrence of necrosis, which led to a second neurosurgery. The diagnosis of glioblastoma was confirmed by neuropathological examination in both cases but with much higher immunohistochemical expression of O(6)-methylguanine-DNA-methyltransferase (MGMT) in the temporal lesion. This report illustrates the potential interest of FDG-PET in multicentric GBMs to identify different metabolic patterns, in accordance with clinical, morphological, and molecular aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568292     DOI: 10.1007/s11060-008-9629-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  20 in total

Review 1.  Brain tumour stem cells.

Authors:  Angelo L Vescovi; Rossella Galli; Brent A Reynolds
Journal:  Nat Rev Cancer       Date:  2006-06       Impact factor: 60.716

2.  Multicentric glioma as a cause of multiple cerebral lesions.

Authors:  W M Chadduck; D Roycroft; M W Brown
Journal:  Neurosurgery       Date:  1983-08       Impact factor: 4.654

3.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors:  M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

4.  Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin.

Authors:  Mukesh K Sharma; David B Mansur; Guido Reifenberger; Arie Perry; Jeffrey R Leonard; Kenneth D Aldape; Meredith G Albin; Ryan J Emnett; Simon Loeser; Mark A Watson; Rakesh Nagarajan; David H Gutmann
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

5.  Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors.

Authors:  T Schifter; J M Hoffman; M W Hanson; O B Boyko; C Beam; S Paine; S C Schold; P C Burger; R E Coleman
Journal:  J Comput Assist Tomogr       Date:  1993 Jul-Aug       Impact factor: 1.826

Review 6.  Multicentric glioma: our experience in 25 patients and critical review of the literature.

Authors:  Maurizio Salvati; Emanuela Caroli; Epimenio Ramundo Orlando; Alessandro Frati; Spartaco Artizzu; Luigi Ferrante
Journal:  Neurosurg Rev       Date:  2003-07-26       Impact factor: 3.042

7.  Multicentric glioma studied with positron emission tomography: a case report.

Authors:  K Sato; M Kameyama; K Ishiwata; T Kayama; T Yoshimoto; M Ito
Journal:  Surg Neurol       Date:  1994-07

8.  Stem cell marker CD133 affects clinical outcome in glioma patients.

Authors:  Felix Zeppernick; Rezvan Ahmadi; Benito Campos; Christine Dictus; Burkhard M Helmke; Natalia Becker; Peter Lichter; Andreas Unterberg; Bernhard Radlwimmer; Christel C Herold-Mende
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

9.  Multicentric glioblastoma multiforme determined by positron emission tomography: a case report.

Authors:  Ajay Jawahar; Christina Weilbaecher; Cedric Shorter; Nancy Stout; Anil Nanda
Journal:  Clin Neurol Neurosurg       Date:  2003-12       Impact factor: 1.876

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  6 in total

1.  Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.

Authors:  Cécile Colavolpe; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Béquet-Boucard; Dominique Figarella-Branger; Olivier Mundler; Olivier Chinot; Eric Guedj
Journal:  J Neurooncol       Date:  2011-12-15       Impact factor: 4.130

2.  FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

Authors:  Cécile Colavolpe; Olivier Chinot; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Bequet-Boucard; Emeline Tabouret; Olivier Mundler; Dominique Figarella-Branger; Eric Guedj
Journal:  Neuro Oncol       Date:  2012-02-29       Impact factor: 12.300

3.  18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma.

Authors:  Ziren Kong; Yusong Lin; Chendan Jiang; Longfei Li; Zehua Liu; Yuekun Wang; Congxin Dai; Delin Liu; Xuying Qin; Yu Wang; Zhenyu Liu; Xin Cheng; Jie Tian; Wenbin Ma
Journal:  Cancer Imaging       Date:  2019-08-19       Impact factor: 3.909

Review 4.  Multicentric Glioma: An Ideal Model to Reveal the Mechanism of Glioma.

Authors:  Yong Yan; Wei Dai; Qiyong Mei
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

5.  Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas.

Authors:  Keisuke Miyake; Aya Shinomiya; Masaki Okada; Tetsuhiro Hatakeyama; Nobuyuki Kawai; Takashi Tamiya
Journal:  J Biomed Biotechnol       Date:  2012-04-11

Review 6.  Usefulness of positron emission tomographic studies for gliomas.

Authors:  Keisuke Miyake; Daisuke Ogawa; Masaki Okada; Tetsuhiro Hatakeyama; Takashi Tamiya
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-05-31       Impact factor: 1.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.